Jerome Mathias, MD
Interventional Cardiology · Midwest City, OKNPI 1780780551
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 92.7% of the total across 466 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 12.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $2,952 and has fallen 72.8% since, to $803 in 2025.
Across 466 payments — averaging $23.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$1K
- Boehringer Ingelheim$1K
- Medtronic$1K
- AstraZeneca$1K
- Merck$990
- Amgen$799
- plus $4K from 23 others
What the payments were for
- Travel & lodging$7797%
- Food & beverage$9,96193%
- Education$90%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 76 | $1,344 |
| Boehringer Ingelheim | 56 | $1,306 |
| Medtronic(2 entities) | 9 | $1,083 |
| AstraZeneca | 26 | $1,063 |
| Merck | 52 | $990 |
| Amgen | 43 | $799 |
| Novartis | 44 | $758 |
| Novo Nordisk | 23 | $701 |
| Esperion Therapeutics, Inc. | 15 | $572 |
| E.r. Squibb & Sons, L.L.C. | 20 | $445 |
| Amarin Pharma, Inc. | 18 | $311 |
| Lilly USA, LLC | 23 | $237 |
| Vifor Pharma, Inc. | 10 | $189 |
| Daiichi Sankyo Inc. | 10 | $167 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $133 |
| Pfizer | 8 | $123 |
| Lexicon Pharmaceuticals, Inc. | 5 | $95 |
| Regeneron Healthcare Solutions, Inc. | 6 | $87 |
| Bayer | 4 | $74 |
| Abbott | 3 | $68 |
| Otsuka America Pharmaceutical, Inc. | 2 | $41 |
| Sanofi-aventis U.S. LLC | 2 | $31 |
| Edwards Lifesciences | 2 | $30 |
| Kestra Medical Technology Services, Inc. | 1 | $26 |
| Lundbeck LLC | 1 | $21 |
| Atricure, Inc. | 1 | $18 |
| Gilead | 1 | $13 |
| Irhythm Technologies, Inc. | 1 | $13 |
| Si-bone, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,749 in reported general payments places this provider in the 65th percentile of 110 interventional cardiology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 122 | $150,655 |
| XareltoRivaroxaban | 169 | $141,369 |
| OzempicSemaglutide | 83 | $98,549 |
| TrulicityDulaglutide | 62 | $92,819 |
| JardianceEmpagliflozin | 73 | $87,040 |
| EntrestoSacubitril/Valsartan | 83 | $85,774 |
| FarxigaDapagliflozin Propanediol | 32 | $31,016 |
| Repatha SureclickEvolocumab | 20 | $16,422 |
| VascepaIcosapent Ethyl | 20 | $7,567 |
| Potassium Chloride | 258 | $7,287 |
| Telmisartan | 188 | $7,121 |
| Ezetimibe | 270 | $6,035 |
| Rosuvastatin Calcium | 360 | $5,059 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 85 | $4,516 |
| Telmisartan-HydrochlorothiazidTelmisartan/Hydrochlorothiazid | 48 | $4,399 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $123 | $150,655122 claims |
| Johnson & JohnsonXarelto | $1,344 | $141,369169 claims |
| Novo NordiskOzempic | $701 | $98,54983 claims |
| Lilly USA, LLCTrulicity | $237 | $92,81962 claims |
| Boehringer IngelheimJardiance | $1,306 | $87,04073 claims |
| NovartisEntresto | $758 | $85,77483 claims |
| AstraZenecaFarxiga | $1,063 | $31,01632 claims |
| Sanofi-aventis U.S. LLCLantus | $31 | $84111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 110 interventional cardiology providers in Oklahoma.
Other interventional cardiology in Midwest City
- Suresh ChandrasekaranMidwest City$302K
- Mohammed AhmedMidwest City$9K
- Kamran MuhammadTulsa$1.4M
- George ChrysantOklahoma City$524K
- Jeffrey SparlingOklahoma City$231K
- Stanley ZimmermanTulsa$93K
- Thomas McGarryOklahoma City$80K
- Usman BaberOklahoma City$76K
- Matthew ComstockTulsa$69K
- Wayne LeimbachTulsa$68K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.